Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC

This study will explore the efficacy and safety of benmelstobart combined with radiochemotherapy compared to radiochemotherapy alone as neoadjuvant treatment for esophageal squamous cell carcinoma. It will also compare the effectiveness and safety of low-dose radiotherapy versus standard-dose radiotherapy in neoadjuvant regimens that include benmelstobart with concurrent radiochemotherapy. This research may provide more treatment options for patients with esophageal squamous cell carcinoma.

Trial Details

NCT ID
NCT06637163
Phase
PHASE2
Sponsor
Shanghai Zhongshan Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy
  • Paclitaxel + Carboplatin + Radiotherapy
Locations (sample)
  • Shantou, Guangdong, China|23.35489,116.67876
  • Shenyang, Liaoning, China|41.79222,123.43278
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Patients voluntarily participate in this study and sign informed consent forms, with good compliance.
  • Aged 18 years and older, regardless of gender.
  • ECOG performance status: 0-1.
  • Patients with histologically confirmed clinical stages T1-3N+M0 or T3NanyM0 of resectable esophageal squamous cell carcinoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →